Upregulated serum L-FABP levels are related to the degree of hepatic fibrosis and inflammation, which indicates serum L-FABP can be a non-invasive marker to assess the severity of fibrosis and inflammation in NAFLD patients [79]. This evidence concerns the gene FABP1 and Hepatic fibrosis.